Diagnostic and Therapeutic Pathways in Cardiac Heart Failure

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 828

Special Issue Editors


E-Mail Website
Guest Editor
University Cardiology Unit, Interdisciplinary Department of Medicine, “Aldo Moro” University School of Medicine, Polyclinic University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
Interests: atrial fibrillation; chronic heart failure; cardiomyopathies; electrocardiography; pacemakers; blood pressure; cardiac electrophysiology; heart rate variability; clinical electrophysiology; channelopathies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Cardiology Unit, Interdisciplinary Department of Medicine (DIM), University of Bari “Aldo Moro”, University Hospital Consortium Polyclinic of Bari, Piazza G. Cesare 11, 70124 Bari, Italy
Interests: cardiology; cardiac magnetic resonance imaging; ecocardiography; bradyarrhythmia; tachyarrhythmia; atrial fibrillation; cardiomyopathies; hypertrophic cardiomyopathy; dilatated cardiomyopathy; arrythmogenic right ventricle cardiomyopathy; amyloidosis; Anderson–Fabry disease; heart failure; Brugada syndrome; channelopathies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure (HF) remains a major global health challenge, with increasing prevalence due to an aging population and improved survival of individuals with cardiovascular diseases. Despite significant advances, many aspects of HF diagnosis and management still present substantial challenges.

In terms of diagnosis, early detection remains elusive, and existing biomarkers and imaging techniques often fail to provide timely and accurate assessments of disease progression. There is an urgent need for novel diagnostic pathways that can enhance risk stratification, predict disease trajectory, and identify subclinical heart failure before irreversible damage occurs.

Therapeutically, while treatment options have expanded, heart failure management is still far from optimal. Despite the success of pharmacologic therapies and devices, many patients remain symptomatic, and clinical outcomes vary widely. New therapeutic strategies, including personalized medicine approaches, gene therapies, and novel drug classes, offer exciting possibilities but also pose significant challenges in terms of efficacy, safety, and accessibility.

We invite researchers in the field of cardiology to share their latest work exploring innovative diagnostic and therapeutic pathways in heart failure. Your research can help shape the future of heart failure care, improving patient outcomes and advancing our understanding of this complex disease.

Please submit your contributions; we look forward to your insights.

Dr. Vincenzo Ezio Santobuono
Prof. Dr. Andrea Igoren Guaricci
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • cardiomyopathies
  • pharmacologic therapies
  • device therapies
  • biomarkers
  • genetic testing
  • sudden cardiac death
  • cardiac MRI

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 705 KiB  
Article
Eligibility of Outpatients with Chronic Heart Failure for Vericiguat and Omecamtiv Mecarbil: From Clinical Trials to the Real-World Practice
by Paolo Basile, Alessio Falagario, Maria Cristina Carella, Marco Maria Dicorato, Francesco Monitillo, Daniela Santoro, Maria Ludovica Naccarati, Gianluca Pontone, Marco Matteo Ciccone, Vincenzo Ezio Santobuono and Andrea Igoren Guaricci
J. Clin. Med. 2025, 14(6), 1951; https://doi.org/10.3390/jcm14061951 - 13 Mar 2025
Viewed by 600
Abstract
Background: Several drugs are emerging as potential therapeutic resources in the context of chronic heart failure (CHF), although their impact on daily clinical practice remains unknown. The objective of this study was to investigate the theoretical eligibility for vericiguat and omecamtiv mecarbil [...] Read more.
Background: Several drugs are emerging as potential therapeutic resources in the context of chronic heart failure (CHF), although their impact on daily clinical practice remains unknown. The objective of this study was to investigate the theoretical eligibility for vericiguat and omecamtiv mecarbil (OM) in a real-world outpatient setting. Methods: A cross-sectional observational study was conducted, enrolling all patients with CHF who had at least one visit between January 2023 and January 2024 in a dedicated outpatient clinic of a tertiary referral center. Theoretical eligibility for vericiguat and OM in our population was assessed by adopting the criteria of the respective phase III clinical trials (VICTORIA trial for vericiguat and GALACTIC-HF trial for OM). Results: In 350 patients with CHF, the rate of individuals eligible was 2% for vericiguat and 4% for OM. A value for left ventricular ejection fraction (LVEF) over the clinical trials’ cutoffs was observed in 41% of cases for vericiguat and 69% for OM. The absence of a recent heart failure (HF) worsening was found in 78% of cases for vericiguat and 72% for OM. Conclusions: Only a small proportion of CHF patients would be eligible for vericiguat and OM in a real-world outpatient setting. The absence of a recent HF worsening and an LVEF over the established trials’ cutoffs are the main causes of non-eligibility. Further studies are required to assess the efficacy of these drugs in a wider population in order to increase the candidates for these beneficial treatments. Full article
(This article belongs to the Special Issue Diagnostic and Therapeutic Pathways in Cardiac Heart Failure)
Show Figures

Figure 1

Back to TopTop